Cargando…
Patient-reported outcomes and health status associated with chronic graft-versus-host disease
Chronic graft-versus-host disease occurs in 20–50% of allogeneic hematopoietic cell transplant survivors. We surveyed patients about their quality of life, symptoms, health status, comorbid conditions and medications. Instruments included the Short-Form-36 (SF-36), the Patient-Reported Outcomes Meas...
Autores principales: | Lee, Stephanie J., Onstad, Lynn, Chow, Eric J., Shaw, Bronwen E., Jim, Heather S.L., Syrjala, Karen L., Baker, K. Scott, Buckley, Sarah, Flowers, Mary E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119141/ https://www.ncbi.nlm.nih.gov/pubmed/29858386 http://dx.doi.org/10.3324/haematol.2018.192930 |
Ejemplares similares
-
Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression
por: Manjappa, Shivaprasad, et al.
Publicado: (2022) -
Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival
por: Pidala, Joseph, et al.
Publicado: (2021) -
Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease
por: Chen, George L., et al.
Publicado: (2022) -
Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease
por: DePriest, Brittany Paige, et al.
Publicado: (2022) -
EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
por: Schoemans, Helene M., et al.
Publicado: (2018)